Print Share Email Twitter Facebook Linkedin Reddit Get Citation Citation AMA Citation Wu C, Ramjaun A. Wu C, Ramjaun A Wu, Constance, and Aliya Ramjaun. "Quick Take: The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults." 2 Minute Medicine, 18 June 2015. McGraw-Hill, New York, NY, 2015. AccessPediatrics. http://accesspediatrics.mhmedical.com/updatesContent.aspx?gbosid=479448§ionid=220610166 MLA Citation Wu C, Ramjaun A. Wu C, Ramjaun A Wu, Constance, and Aliya Ramjaun.. "Quick Take: The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults." 2 Minute Medicine New York, NY: McGraw-Hill, 2015, http://accesspediatrics.mhmedical.com/updatesContent.aspx?gbosid=479448§ionid=220610166. Download citation file: RIS (Zotero) EndNote BibTex Medlars ProCite RefWorks Reference Manager Mendeley © Copyright Tools Clip Full Chapter Figures Only Tables Only Videos Only Supplementary Content Top Quick Take: The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults by Constance Wu, Aliya Ramjaun Listen +Originally published by 2 Minute Medicine® (view original article). Reused on AccessPediatrics with permission. +Oral live-attenuated polio vaccines (OPV) and injected inactivated polio vaccines IPV) have helped eradicate wild polioviruses. However, there is still a need to develop new vaccines due to risk of outbreaks of vaccine-derived polioviruses. In the process of developing new vaccines, it is important to study the safety of the viruses and possible release into the environment. In this double-blind phase 1 trial, investigators randomized 30 participants to receive two novel monovalent oral type-2 poliovirus (OPV2) vaccine candidates in order to study the safety of the vaccines, the nature of viral shedding in participants, and the immunogenic effect of the vaccines. Investigators found that both OPV2 candidates increased the median blood titer of serum neutralizing antibodies, and all participants were seroprotected after vaccination. Severe events were reported in 40% of participants receiving candidate 1, and in 60% of participants receiving candidate 2; most events were increases in blood creatinine phosphokinase without accompanying clinical symptoms. There were no serious adverse events. In terms of shedding, 100% of participants receiving vaccine candidate 1 and 87% of participants receiving candidate 2 had vaccine virus detected in their stools. Viral shedding stopped after a median of 23 days (IQR 15-36 days) and 12 days (IQR 1-23) for candidates 1 and 2, respectively. Overall, the results from this study indicate an acceptable safety profile for the two vaccine candidates and a shedding rate that is not substantially increased compared to existing vaccines. As such, these candidates hold promise for future studies. Limitations for this study include the small sample size and the lack of placebo group. +Click to read the study in Lancet +©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.